WO2001070955A3 - Identification of essential genes in prokaryotes - Google Patents

Identification of essential genes in prokaryotes Download PDF

Info

Publication number
WO2001070955A3
WO2001070955A3 PCT/US2001/009180 US0109180W WO0170955A3 WO 2001070955 A3 WO2001070955 A3 WO 2001070955A3 US 0109180 W US0109180 W US 0109180W WO 0170955 A3 WO0170955 A3 WO 0170955A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
proliferation
screen
proteins
prokaryotes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/009180
Other languages
French (fr)
Other versions
WO2001070955A8 (en
WO2001070955A2 (en
Inventor
Robert Haselbeck
Kari L Ohlsen
Judith W Zyskind
Daniel Wall
John D Trawick
Grant J Carr
Robert T Yamamoto
H Howard Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elitra Pharmaceuticals Inc
Original Assignee
Elitra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elitra Pharmaceuticals Inc filed Critical Elitra Pharmaceuticals Inc
Priority to CA002404260A priority Critical patent/CA2404260A1/en
Priority to EP01922557A priority patent/EP1268774A2/en
Priority to JP2001569338A priority patent/JP4852211B2/en
Priority to AU2001249345A priority patent/AU2001249345A1/en
Publication of WO2001070955A2 publication Critical patent/WO2001070955A2/en
Publication of WO2001070955A3 publication Critical patent/WO2001070955A3/en
Anticipated expiration legal-status Critical
Publication of WO2001070955A8 publication Critical patent/WO2001070955A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate molecules for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than Staphylococcus aureus, Salmonella typhimurium, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms.
PCT/US2001/009180 2000-03-21 2001-03-21 Identification of essential genes in prokaryotes Ceased WO2001070955A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002404260A CA2404260A1 (en) 2000-03-21 2001-03-21 Identification of essential genes in prokaryotes
EP01922557A EP1268774A2 (en) 2000-03-21 2001-03-21 Identification of essential genes in prokaryotes
JP2001569338A JP4852211B2 (en) 2000-03-21 2001-03-21 Identification of essential genes in prokaryotes
AU2001249345A AU2001249345A1 (en) 2000-03-21 2001-03-21 Identification of essential genes in prokaryotes

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US19107800P 2000-03-21 2000-03-21
US60/191,078 2000-03-21
US20684800P 2000-05-23 2000-05-23
US60/206,848 2000-05-23
US20772700P 2000-05-26 2000-05-26
US60/207,727 2000-05-26
US24257800P 2000-10-23 2000-10-23
US60/242,578 2000-10-23
US25362500P 2000-11-27 2000-11-27
US60/253,625 2000-11-27
US25793100P 2000-12-22 2000-12-22
US60/257,931 2000-12-22
US26930801P 2001-02-16 2001-02-16
US60/269,308 2001-02-16

Publications (3)

Publication Number Publication Date
WO2001070955A2 WO2001070955A2 (en) 2001-09-27
WO2001070955A3 true WO2001070955A3 (en) 2002-08-01
WO2001070955A8 WO2001070955A8 (en) 2004-04-15

Family

ID=27569239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/009180 Ceased WO2001070955A2 (en) 2000-03-21 2001-03-21 Identification of essential genes in prokaryotes

Country Status (7)

Country Link
US (1) US20020061569A1 (en)
EP (1) EP1268774A2 (en)
JP (1) JP4852211B2 (en)
KR (1) KR20020097200A (en)
AU (1) AU2001249345A1 (en)
CA (1) CA2404260A1 (en)
WO (1) WO2001070955A2 (en)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503619A (en) * 1996-01-19 1999-03-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Staphylococcus aureus methionyl-tRNA synthetase
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
CA2365523A1 (en) * 1999-04-15 2000-10-26 The Regents Of The University Of California Identification of sortase gene
US7101692B2 (en) * 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
US7125698B2 (en) * 1999-08-09 2006-10-24 Matthew Glenn Polynucleotides, materials incorporating them, and methods for using them
CA2386235A1 (en) * 1999-10-04 2001-04-12 Merck & Co., Inc. Mray gene and enzyme of pseudomonas aeruginosa
US6861516B1 (en) 1999-10-04 2005-03-01 Merck & Co., Inc. MraY gene and enzyme of pseudomonas aeruginosa
US20020120408A1 (en) * 2000-09-06 2002-08-29 Kreiswirth Barry N. System and method for tracking and controlling infections
US7349808B1 (en) 2000-09-06 2008-03-25 Egenomics, Inc. System and method for tracking and controlling infections
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
BR0116756A (en) 2000-12-28 2005-01-04 Wyeth Corp Recombinant protective protein for streptococcus pneumoniae and its use
AT410798B (en) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh METHOD FOR IDENTIFYING, ISOLATING AND PRODUCING ANTIGENS AGAINST A SPECIFIC PATHOGEN
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002307448A1 (en) * 2001-04-20 2002-11-05 President And Fellows Of Harvard College Methods and compositions for the modulation of biofilm formation
WO2003025004A2 (en) * 2001-09-18 2003-03-27 Affinium Pharmaceuticals, Inc. Purified bacterial polypeptides involved in nucleic acid processing
WO2003045985A2 (en) * 2001-11-26 2003-06-05 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in carbohydrate and coenzyme metabolism
AU2002328225A1 (en) * 2001-09-21 2003-04-01 Affinium Pharmaceuticals, Inc. Bacterial polypeptides involved in protein processing
AU2002331473A1 (en) * 2001-09-25 2003-04-07 Affinium Pharmaceuticals, Inc. Purified polypeptides from pseudomonas aeruginosa
EP1438434A4 (en) * 2001-09-26 2006-03-08 Merck & Co Inc INSULATED NUCLEIC ACID MOLECULES ENCODING A BACTERIAL URACIL TRANSPORT PROTEIN AND A BACTERIAL URACIL PHOSPHORIBOSYL TRANSFERASE ENZYME, CELLS TRANSFORMED THEREFROM, AND USES THEREOF
EP1930420A1 (en) * 2001-09-26 2008-06-11 Merck & Co., Inc. Isolated nucleic acid molecules encoding a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
SI1456380T1 (en) * 2001-11-02 2012-11-30 Giuliani Int Ltd Smad7 inhibitors for the treatment of cns diseases
RU2229513C2 (en) 2001-11-23 2004-05-27 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" Method for preparing l-amino acids, strain escherichia coli as producer of l-amino acids (variants)
AU2002364771A1 (en) * 2001-11-26 2003-06-10 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in general metabolism as possible drug targets
TW200303919A (en) * 2001-12-05 2003-09-16 Hiroyuki Ohno Cytotoxic protein and the use
US20030170694A1 (en) * 2001-12-21 2003-09-11 Daniel Wall Stabilized nucleic acids in gene and drug discovery and methods of use
WO2003066849A2 (en) * 2002-02-04 2003-08-14 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from staphylococcus aureus
US6946267B2 (en) * 2002-03-13 2005-09-20 Dr. Chip Biotechnology Inc. Method for detecting Staphylococcus aureus
US8691243B2 (en) 2002-04-02 2014-04-08 Ben-Gurion University Of The Negev Research And Development Authority Protein-based Streptococcus pneumoniae vaccine
US20090252756A1 (en) * 2002-04-02 2009-10-08 Yaffa Mizrachi-Nebenzahl Protein-based streptococcus pneumoniae vaccines
WO2003102190A2 (en) * 2002-05-31 2003-12-11 Affinium Pharmaceuticals, Inc. Bacterial polypeptides involved in viability
WO2003087146A2 (en) * 2002-04-08 2003-10-23 Affinium Pharmaceuticals, Inc. Purified polypeptides from s. aureus, h. pylori and e. coli involved in cellular transport and metabolism
AU2003213949A1 (en) * 2002-04-08 2003-10-27 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in membrane biogenesis
WO2003087352A2 (en) * 2002-04-09 2003-10-23 Affinium Pharmaceuticals, Inc. Enolase polypeptides and structures
WO2003089463A1 (en) * 2002-04-17 2003-10-30 Affinium Pharmaceuticals, Inc. Purified (3r)-hydroxymyristoyl-(acyl-carrier-protein) dehydratase polypeptide from pseudomonas aeruginosa
US7432061B2 (en) * 2002-05-31 2008-10-07 Biozyme, Inc. Assays for measuring matrix metalloproteinase activities
EP1552009A4 (en) * 2002-07-17 2006-09-13 Merck & Co Inc METHOD OF IDENTIFYING CELL GROWTH INHIBITORS
WO2004013167A2 (en) * 2002-08-01 2004-02-12 Affinium Pharmaceuticals, Inc. Purified polypeptides from enterococcus faecalis
WO2004018624A2 (en) * 2002-08-20 2004-03-04 Chiron Corporation Random transposon insertion in staphylococcus aureus and use thereof to identify essential genes
WO2004018646A2 (en) * 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
WO2004041854A2 (en) * 2002-11-05 2004-05-21 Affinium Pharmaceuticals, Inc. Essential novel bacterial polypeptides
WO2004042045A2 (en) * 2002-11-05 2004-05-21 Affinium Pharmaceuticals, Inc. Crystal structures of bacterial thymidylate kinases
FR2846668B1 (en) * 2002-11-05 2007-12-21 Univ Aix Marseille Ii MOLECULAR IDENTIFICATION OF BACTERIA OF THE GENUS STREPTOCOCCUS AND RELATED GENRES
WO2004058812A2 (en) * 2002-12-26 2004-07-15 Affinium Pharmaceuticals, Inc. Ribose-phosphate pyrophosphokinase polypeptides and structures
WO2004081206A2 (en) * 2003-03-12 2004-09-23 Affinium Pharmaceuticals, Inc. Novel polypeptides encoded by essential bacterial genes
AU2003287825A1 (en) * 2002-12-31 2004-07-22 Affinium Pharmaceuticals, Inc. Crystal structures of nh3-dependent nad synthetases
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
JP5642916B2 (en) * 2003-04-17 2014-12-17 ザ スクリプス リサーチ インスティテュート Expansion of the eukaryotic genetic code
US20050026189A1 (en) * 2003-05-29 2005-02-03 Liangsu Wang Microbial operons
US7709009B2 (en) * 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
EP1670505B1 (en) * 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna promoters and anthrax vaccines
US8329192B2 (en) 2003-09-19 2012-12-11 Epitopix Llc Campylobacter polypeptides and methods of use
US20050176033A1 (en) * 2003-11-10 2005-08-11 Klyachko Elena V. Mutant phosphoribosylpyrophosphate synthetase and method for producing L-histidine
US20080138835A1 (en) * 2004-05-07 2008-06-12 Replidyne, Inc. Mutants of Staphylococcal Mrs and Methods of Use
JP2008507296A (en) * 2004-07-26 2008-03-13 ナノスフェアー　インコーポレイテッド A method for distinguishing methicillin-resistant Staphylococcus aureus from methicillin-sensitive Staphylococcus aureus in mixed cultures
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
US20060078952A1 (en) * 2004-09-14 2006-04-13 Carine Robichon Method for identifying antimicrobial molecules which interfere with apolipoprotein N-acyltransferase activity
EP1791560A4 (en) * 2004-09-17 2009-01-14 Merck & Co Inc POLYPEPTIDES FOR INDUCING AN IMMUNE RESPONSE OF PROTECTION DIRECTED AGAINST STAPHYLOCOCCUS AUREUS
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
DE102004055508A1 (en) 2004-11-17 2006-06-01 Basf Ag Process for the preparation of optically active alcohols
WO2006078680A2 (en) * 2005-01-21 2006-07-27 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
CA2595163A1 (en) 2005-01-21 2006-07-27 Epitopix, Llc Yersinia peptides grown in media comprising 2,2'-dipyridyl, compositions and kits thereof
NZ597997A (en) 2005-02-14 2013-10-25 Epitopix Llc Antibody compositions that bind polypeptides from staphylococcus aureus
GB0505949D0 (en) * 2005-03-23 2005-04-27 Univ Sheffield Polypeptides
AU2006235045A1 (en) * 2005-03-30 2006-10-19 J. Craig Venter Institute, Inc. Haemophilus influenzae type b
US20090132178A1 (en) * 2005-08-03 2009-05-21 Dharamsi Akil I Crystalline enoyl-(acyl-carrier-protein) Reductase from Heliobacter Pylori
US8945899B2 (en) 2007-12-20 2015-02-03 Butamax Advanced Biofuels Llc Ketol-acid reductoisomerase using NADH
WO2007055288A1 (en) 2005-11-10 2007-05-18 National University Of Corporation Hiroshima University Method and agent for immobilizing protein via protein bound to silicon oxide containing-substance
WO2007106536A2 (en) 2006-03-14 2007-09-20 Oregon Health & Science University Methods for producing an immune response to tuberculosis
DK2054431T3 (en) * 2006-06-09 2012-01-02 Novartis Ag Conformers of bacterial adhesins
US20090275058A1 (en) * 2006-09-14 2009-11-05 Universitat De Girona Method for specific detection of salmonella spp.
FR2906532B1 (en) * 2006-09-28 2008-12-12 Biomerieux Sa NEW OLIGONUCLEOTIDE BRAND
JPWO2008044599A1 (en) * 2006-10-06 2010-02-12 プロテウスサイエンス株式会社 Polypeptide having inflammatory intestinal target activity and use thereof
AU2007348285A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
NZ579780A (en) * 2007-04-18 2012-07-27 Butamax Advanced Biofuels Llc Fermentive production of isobutanol using highly active ketol-acid reductoisomerase enzymes
JP2010524454A (en) 2007-04-19 2010-07-22 モレキュラー ディテクション インコーポレーテッド Methods, compositions and kits for detection and analysis of antibiotic resistant bacteria
JP2010183841A (en) * 2007-05-29 2010-08-26 Ajinomoto Co Inc Method for producing l-amino acid
KR20100072228A (en) 2007-08-31 2010-06-30 유니버시티 오브 시카고 Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
BRPI0821748A2 (en) * 2007-12-19 2019-09-24 Basf Plant Science Gmbh method for producing a plant with increased yield, isolated nucleic acid molecule, nucleic acid construction, vector, process for producing a polypeptide, polypeptide, antibody, plant cell nucleus, plant cell, plant tissue, propagation material, seed, pollen, progeny, or a plant part, or a high yielding plant, process for the identification of a compound, method for producing an agricultural composition, composition, polypeptide or nucleic acid molecule, use of nucleic acids, and method for the identification of a plant with increased yield
NZ586430A (en) 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
FI20075976A0 (en) * 2007-12-31 2007-12-31 Finnzymes Oy Methods and oligonucleotides for detecting bacteria that cause mastitis
EP2252702B1 (en) 2008-02-08 2014-01-29 Mayo Foundation for Medical Education and Research Detection of clostridium difficile
SI2268618T1 (en) 2008-03-03 2015-09-30 Novartis Ag Compounds and compositions as tlr activity modulators
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
KR100975956B1 (en) * 2008-08-08 2010-08-13 주식회사 콤슨테크놀러지 Mobile device for the disabled with sterilization function
CA2758687A1 (en) * 2008-11-14 2010-05-20 Gen-Probe Incorporated Compositions, kits and methods for detection of campylobacter nucleic acid
EP2376111A4 (en) * 2008-11-26 2013-01-09 Merck Sharp & Dohme POLYPEPTIDES FOR INDUCING PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS
NZ614557A (en) * 2009-03-23 2015-03-27 Epitopix Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
HRP20160274T1 (en) 2009-04-03 2016-04-08 University Of Chicago PREPARATIONS AND METHODS RELATED TO PROTEIN A (SPA) VARIATIONS
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
JO3257B1 (en) 2009-09-02 2018-09-16 Novartis Ag Vehicles and installations as TLR
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP5814933B2 (en) 2009-12-15 2015-11-17 ノバルティス アーゲー Homogeneous suspension of immune enhancing compounds and uses thereof
EA031379B1 (en) 2010-03-23 2018-12-28 Новартис Аг Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
LT3444268T (en) 2010-05-05 2022-04-11 New York University STAPHYLOCOCCUS AUREUS LEUKOCIDINES, THERAPEUTIC COMPOSITIONS AND THEIR USES
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012090789A1 (en) * 2010-12-28 2012-07-05 国立大学法人広島大学 Polypeptide for distinguishing silicon oxide from silicon nitride, and use thereof
EP2689014B1 (en) 2011-03-24 2019-04-24 Butamax (TM) Advanced Biofuels LLC Host cells and methods for production of isobutanol
EP2694534B1 (en) * 2011-04-08 2018-06-20 Evaxion Biotech ApS Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
GB201116767D0 (en) 2011-09-28 2011-11-09 St George S Hospital Medical School Treatment for mitrochondrial neurogastrointestinal encephalomyopathy
WO2013066733A1 (en) * 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2074 protein
EP2812434B1 (en) * 2012-02-09 2018-03-28 Bavarian Nordic A/S Agonists and antagonists of toll-like receptor (tlr) 13
US9181568B2 (en) * 2012-04-23 2015-11-10 Exxonmobil Research And Engineering Company Cell systems and methods for improving fatty acid synthesis by expression of dehydrogenases
WO2013162746A1 (en) * 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
MX2014013446A (en) 2012-05-11 2014-12-08 Butamax Advanced Biofuels Llc Ketol-acid reductoisomerase enzymes and methods of use.
EP2872173A4 (en) 2012-07-10 2016-03-23 Merck Sharp & Dohme STAPHYLOCOCCUS AUREUS SA2493 PROTEIN PROTECTIVE VACCINE
JP2015529677A (en) * 2012-09-19 2015-10-08 ノバルティス アーゲー Clostridium difficile polypeptide as a vaccine
AU2013323427A1 (en) 2012-09-26 2015-03-05 Butamax (Tm) Advanced Biofuels Llc Polypeptides with ketol-acid reductoisomerase activity
BR112015008621A2 (en) * 2012-10-17 2018-08-28 Enterome METHODS AND DIAGNOSTIC AND / OR PROGNOSTIC KIT IN VITRO NUCLEIC ACID MICRO-ASSEMBLY.
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
KR20150013092A (en) * 2013-07-26 2015-02-04 삼성전자주식회사 Bacterial cell having enhanced succinic acid production and a method for producing the succinic acid using the same
WO2015021058A2 (en) 2013-08-05 2015-02-12 Greenlight Biosciences, Inc. Engineered proteins with a protease cleavage site
US10100093B2 (en) 2013-12-31 2018-10-16 Epitopix Llc Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use
WO2015171693A1 (en) * 2014-05-06 2015-11-12 Virginia Commonwealth University A new target for firmicutes and related bacteria: the prp protease
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
HRP20191671T1 (en) 2014-05-09 2019-12-13 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
FR3024903A1 (en) 2014-08-14 2016-02-19 Biomerieux Sa METHOD FOR QUANTIFYING AT LEAST ONE GROUP OF MICROORGANISMS BY MASS SPECTROMETRY
TWI649331B (en) * 2015-06-11 2019-02-01 國立中興大學 Acinetobacter baumannii (Acinetobacter baumaniini) multiple peptide antigen and its antibody and nucleic acid encoding the antigen
JP6938482B2 (en) * 2015-10-02 2021-09-22 ユニバーシティー オブ ユタ リサーチ ファンデーション Compositions and Usage for Adjustable Ribosome Translation Rate
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
KR102050870B1 (en) * 2017-04-06 2019-12-02 포항공과대학교 산학협력단 Modulation of plasmid copy number in antibiotics-free plasmid maintenance system
BR112020016314A2 (en) 2018-02-12 2020-12-15 Inimmune Corporation PHARMACEUTICALLY ACCEPTABLE COMPOUNDS OR SALTS, PHARMACEUTICAL COMPOSITION, KIT, AND, METHODS FOR ELICITATING, INTENSIFYING OR MODIFYING AN IMMUNOLOGICAL RESPONSE, TO TREAT, PREVENT OR REDUCE THE SUSCETIBILITY TO CANCER, TO REDUCE, UNDERSTAND TREAT, PREVENT OR REDUCE SUSCEPTIBILITY TO AN ALLERGY, TO TREAT, PREVENT OR REDUCE SUSCETIBILITY TO AUTOIMMUNE AFFECTION, TO TREAT, PREVENT OR REDUCE SUSCETIBILITY IN A SUBJECT TO BACTERIAL INFECTION, ALTERNATE, VENEER, NAVAL, NAVARI TREAT, PREVENT OR REDUCE SUSCEPTIBILITY TO AUTOIMMUNITY, ALLERGY, ISCHEMIA OR SEPSIS REPERFUSION, TO TREAT, PREVENT OR REDUCE THE GRAVITY OF EPILETIC ATTACKS AND TO TREAT, PREVENT OR REDUCE THE MACANTIC HERITAGE OF HERITAGE,
WO2019169258A1 (en) * 2018-03-01 2019-09-06 The Regents Of The University Of California Methods and compositions relating to epoxide hydrolase genes
CA3139981A1 (en) 2019-05-14 2020-11-19 The University Of Chicago Methods and compositions comprising staphylococcus protein a (spa) variants
US12378583B2 (en) * 2019-08-28 2025-08-05 Inner Mongolia Eppen Biotech Co., Ltd. Escherichia coli-based recombinant strain, construction method therefor and use thereof
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections
JP2022551986A (en) 2019-10-16 2022-12-14 ザ・ブロード・インスティテュート・インコーポレイテッド Modified muscle targeting composition
US20230026969A1 (en) * 2019-12-03 2023-01-26 China Medical University Oligopeptide, Testing Kit Thereof And Medical Composition Thereof
US20230287437A1 (en) * 2020-06-05 2023-09-14 Modernatx, Inc. Bacterial strains for dna production
US12668814B2 (en) 2020-07-22 2026-06-30 The Broad Institute, Inc. Engineered muscle targeting compositions
KR20230117105A (en) 2020-11-04 2023-08-07 엘리고 바이오사이언스 Cutibacterium acnes recombinant phage, manufacturing method and use thereof
EP4399316A4 (en) * 2021-09-08 2025-11-12 Broad Inst Inc COMPOSITIONS OF GENETICALLY MODIFIED MUSCLE AND CENTRAL NERVOUS SYSTEM
CN114032313B (en) * 2021-11-18 2024-09-17 广东海洋大学 A method for evaluating, detecting and/or predicting beef quality traits in yaks
EP4516310A4 (en) * 2022-04-28 2026-04-08 Univ Tokyo BACTERICIDE AGAINST ENTEROCOCCUS FAECALIS
EP4662323A2 (en) * 2023-02-09 2025-12-17 Kate Therapeutics, Inc. Muscle targeted capsids

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021366A1 (en) * 1996-11-13 1998-05-22 Qbi Enterprises, Ltd. Gene identification method
WO1998050555A2 (en) * 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
WO1999002673A2 (en) * 1997-07-10 1999-01-21 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
WO1999013893A1 (en) * 1997-09-16 1999-03-25 Isis Pharmaceuticals, Inc. Peptide nucleic acids having antibacterial activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872104A (en) * 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
US6171838B1 (en) * 1997-08-13 2001-01-09 Smithkline Beecham Corporation ratB
US20020115217A1 (en) * 1997-10-02 2002-08-22 Smithkline Beecham Corporation Whole cell assay
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
KR20010024603A (en) * 1998-09-09 2001-03-26 밀레니엄 파머슈티컬스 인코퍼레이티드 Essential bacterial genes and their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021366A1 (en) * 1996-11-13 1998-05-22 Qbi Enterprises, Ltd. Gene identification method
WO1998050555A2 (en) * 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
WO1999002673A2 (en) * 1997-07-10 1999-01-21 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
WO1999013893A1 (en) * 1997-09-16 1999-03-25 Isis Pharmaceuticals, Inc. Peptide nucleic acids having antibacterial activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EM_PRO 2 November 1995 (1995-11-02), XP002190118 *
GOOD ET AL: "Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA", NATURE BIOTECHNOLOGY, vol. 16, April 1998 (1998-04-01), pages 355 - 358, XP002140166, ISSN: 1087-0156 *
SUH, J.W. ET AL.: "Genetic and transcriptional organization of the Bacillus subtilis spc-alpha region", GENE, vol. 169, 1996, pages 17 - 23, XP004042981 *

Also Published As

Publication number Publication date
EP1268774A2 (en) 2003-01-02
WO2001070955A8 (en) 2004-04-15
KR20020097200A (en) 2002-12-31
CA2404260A1 (en) 2001-09-27
US20020061569A1 (en) 2002-05-23
JP2004516805A (en) 2004-06-10
JP4852211B2 (en) 2012-01-11
AU2001249345A1 (en) 2001-10-03
WO2001070955A2 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
WO2001070955A8 (en) Identification of essential genes in prokaryotes
WO2002077183A9 (en) Identification of essential genes in microorganisms
Ghosh et al. Lysine acetylation of the Mycobacterium tuberculosis HU protein modulates its DNA binding and genome organization
WO2001048209A3 (en) Genes identified as required for proliferation of e. coli
WO2000044906A3 (en) GENES IDENTIFIED AS REQUIRED FOR PROLIFERATION IN $i(ESCHERICHIA COLI)
WO2005042716A3 (en) Nucleic acid binding oligonucleotides
WO2006031800A3 (en) Reverse transfection of cell arrays
WO2000054046A3 (en) Universal protein array system
WO2007085923A8 (en) Novel fluorescent proteins and methods for using same
WO2002008285A3 (en) Il-17 molecules and uses thereof
WO2002004488A3 (en) Nucleic acid binding polypeptides
EP1130091A3 (en) Bacterial RNaseP Proteins and their use in identifying antibacterial compounds
WO2007040592A8 (en) Making nucleic acid sequences in parallel and use
CA3195897A1 (en) Self-targeting expression vector
Paradis-Bleau et al. Peptide inhibitors of the essential cell division protein FtsA
WO2002012478A8 (en) Methyl-d-erythritol phosphate pathway genes
WO2002024912A3 (en) Isolated nucleic acid molecules which encode a soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof
WO2005054438A3 (en) Nucleic acid molecules containing recombination sites and methods of using the same
WO2001096373A3 (en) Fluorescent timer proteins and methods for their use
WO2002010393A3 (en) Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
WO2009086125A3 (en) Affinity tag nucleic acid and protein compositions, and processes for using same
WO2001034810A3 (en) Genes essential for microbial proliferation
WO2003062453A3 (en) Polycystic kidney disease nucleic acids and proteins
WO2007052102A3 (en) Modified green fluorescent proteins and methods for using same
WO2002079495A3 (en) Genomics applications for modified oligonucleotides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 520954

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020027012285

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2404260

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 569338

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001249345

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001922557

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027012285

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001922557

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 39/2001 DUE TO A TECHNICAL PROBLEMAT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING UNDER (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

WWW Wipo information: withdrawn in national office

Ref document number: 2001922557

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)